Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Chromocell Therapeutics Corporation

Healthcare US CHRO

NoneUSD
0.00(0%)

Last update at 2025-10-02T20:12:23.470029Z

Day Range

--
LowHigh

52 Week Range

0.456.00
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap5.34M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.68

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Income before tax -7.38079M -7.38079M -2.45859M -2.45859M -0.59539M
Minority interest - - - - -
Net income -7.38079M -7.38079M -2.45859M -2.45859M -0.59539M
Selling general administrative 4.28M 4.28M 1.93M 1.93M 0.63M
Selling and marketing expenses - - - - -
Gross profit -2.57942M - -0.39173M - -0.20905M
Reconciled depreciation - - - - -
Ebit -13.72456M - -2.31816M - -1.67800M
Ebitda -6.86228M - -1.62771M - -0.83900M
Depreciation and amortization 6.86M - 0.69M - 0.84M
Non operating income net other - - - - -
Operating income -6.86228M -6.86228M -2.31816M -2.31816M -0.83900M
Other operating expenses 6.86M - 2.32M - 0.84M
Interest expense 0.52M 0.52M 0.14M 0.14M 0.00025M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income -0.51851M -0.51851M -0.14043M -0.14043M -0.00025M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.86228M - -0.69045M - -0.83900M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 6.86M 6.86M 2.32M 2.32M 0.84M
Cost of revenue 2.58M - 0.39M - 0.21M
Total other income expense net -0.51851M - -0.14043M - 0.24M
Discontinued operations - - - - -
Net income from continuing ops -7.38079M -7.38079M -2.45859M -2.45859M -0.59539M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Total assets 0.10M 0.10M 0.06M 0.06M 0.00000M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 6.54M 6.54M 3.76M 3.76M 3.68M
Total stockholder equity -6.44455M -6.44455M -3.70654M -3.70654M -3.68027M
Deferred long term liab - - - - -
Other current liab 0.65M - 0.23M - -2.58032M
Common stock 0.00039M - 0.01000M - -
Capital stock 0.00045M 0.00045M 0.00017M 0.00017M 0.00000M
Retained earnings -13.51965M -13.51965M -6.13886M -6.13886M -3.68027M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.10M 0.10M 0.06M 0.06M 0.00000M
Cash and equivalents - - - - -
Total current liabilities 6.54M 6.54M 3.76M 3.76M 2.58M
Current deferred revenue - - 0.00000M - -
Net debt 1.17M 1.17M 0.49M 0.49M 1.10M
Short term debt 1.27M - 0.54M - -
Short long term debt 1.27M 1.27M 0.54M 0.54M -
Short long term debt total 1.27M - 0.54M - 1.10M
Other stockholder equity 7.08M - 2.46M - -
Property plant equipment - - - - -
Total current assets 0.10M 0.10M 0.06M 0.06M 0.00000M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.62M 4.62M 2.99M 2.99M 2.58M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00039M - -0.01000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Investments - - - - -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 1.02M 1.02M 1.62M 1.62M 1.59M
Change to operating activities - - - - -
Net income -7.38079M -7.38079M -2.45859M -2.45859M -0.59539M
Change in cash 0.04M 0.04M 0.06M 0.06M 0.00000M
Begin period cash flow 0.06M 0.06M 0.06M 0.00000M 0.00000M
End period cash flow 0.10M 0.10M 0.06M 0.06M 0.00000M
Total cash from operating activities -0.98103M -0.98103M -1.56715M -1.56715M -1.59301M
Issuance of capital stock 0.26M 0.26M 0.00000M 0.00000M -
Depreciation 0.19M - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 1.02M - 1.22M - 1.59M
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.05M 2.05M 0.64M 0.64M -0.75583M
Stock based compensation 3.96M 1.73M 0.11M 0.11M 0.00000M
Other non cash items 0.20M 2.41M -0.16303M 0.14M 0.59M
Free cash flow -0.98103M -0.98103M -1.56715M -1.56715M -1.59301M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CHRO
Chromocell Therapeutics Corporation		 - -% - - - - 4.11 -3.5773
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Chromocell Therapeutics Corporation

4400 Route 9 South, Freehold, NJ, United States, 07728

Key Executives

Name Title Year Born
Mr. Francis Knuettel II, M.B.A. President, CEO, CFO, Treasurer, Secretary & Director 1966
Dr. Eric Lang M.D. Chief Medical Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.